References: Malignant mesothelioma detailed guide

American Joint Committee on Cancer. Pleural mesothelioma. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 271-274.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181:1383-1390.

National Cancer Institute. Physician Data Query (PDQ). Malignant Mesothelioma: Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/malignantmesothelioma/HealthProfessional on August 2, 2012.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. V.2.2012. Accessed at www.nccn.org/professionals/physician_gls/pdf/mpm.pdf on August 2, 2012.

Pan X, Day W, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Resp Crit Care. 2005;172:1019-1025.

Pass HI, Vogelzgang NJ, Hahn SM, Carbone M. Benign and malignant mesothelioma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:2052-2080.

Price B, Ware A. Mesothelioma trends in the United States: An update based on Surveillance Epidemiology and End Results program date for 1973-2003. Am J Epidemiol. 2004;159:107-112.

Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603.

Sovak MA, Aisner SC, Aisner J. Tumors of the pleura and mediastinum. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1367-1398.

Sterman DH, Haas A, Moon E, et al. A trial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011;184:1395-1399.

Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022-1025.

Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081-2090.